Xolair, co-developed and co-promoted by San Francisco-based Genentech and East Hanover, N.J.-based Novartis, is the first medicine approved to treat CIU since H1-antihistamines, according to the news release.
In 2003, Xolair was approved to treat persistent allergic asthma.
More Articles on FDA Approvals:
FDA Approves Neuraceq for Brain Imaging
FDA Approves Implantable Device for Certain Type of Hearing Loss
FDA Approves Apixaban for New Use
